Published in Br J Cancer on April 01, 1982
Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver. Br J Cancer (1986) 1.58
Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. Br J Cancer (1986) 1.53
meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer (1986) 1.47
Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer. Br J Cancer (1986) 1.36
Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase. Biochem J (1984) 1.30
Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J (1989) 1.19
Preferential delivery of liposome-incorporated porphyrins to neoplastic cells in tumour-bearing rats. Br J Cancer (1983) 0.99
Biological and biophysical properties of the tumor-localizing component of hematoporphyrin derivative. Cancer Res (1985) 0.98
Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. Br J Cancer (1985) 0.94
Retention and photodynamic effects of haematoporphyrin derivative in cells after prolonged cultivation in the presence of porphyrin. Br J Cancer (1983) 0.92
Haematoporphyrin and OO'-diacetylhaematoporphyrin binding by serum and cellular proteins. Implications for the clearance of these photochemotherapeutic agents by cells. Biochem J (1983) 0.87
Interactions with glutathione S-transferases of porphyrins used in photodynamic therapy and naturally occurring porphyrins. Biochem J (1985) 0.79
The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. Br J Cancer (1996) 0.78
CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. Phys Med Biol (2014) 0.78
Photodynamic therapy of a mouse glioma: intracranial tumours are resistant while subcutaneous tumours are sensitive. Br J Cancer (1991) 0.77
Photodynamic therapy with mTHPC and polyethylene glycol-derived mTHPC: a comparative study on human tumour xenografts. Br J Cancer (1999) 0.77
In vitro photosensitization of tumour cell enzymes by photofrin II administered in vivo. Br J Cancer (1989) 0.77
The significance of the nature of the photosensitizer for photodynamic therapy: quantitative and biological studies in the colon. Br J Cancer (1990) 0.76
The effect on photohaemolysis of variation in the structure of the porphyrin photosensitizer. Biochem J (1985) 0.75
Characterization of a murine model for the rapid assessment of acute photodynamic response in tumour and muscle. Lasers Med Sci (1997) 0.75
Photoradiation therapy for the treatment of malignant tumors. Cancer Res (1978) 4.01
The use of a derivative of hematoporhyrin in tumor detection. J Natl Cancer Inst (1961) 2.40
The mechanism of photodynamic inactivation of human cells in vitro in the presence of haematoporphyrin. Br J Cancer (1979) 1.82
Photodynamic destruction of human bladder carcinoma. Br J Cancer (1975) 1.55
Photodynamic therapy of malignant tumours. Lancet (1972) 1.48
Effects of photoactivated porphyrins at the cell surface of leukemia L1210 cells. Biochemistry (1977) 1.39
The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol (1960) 1.34
Measurements on the depth of penetration of light (0.35--1.0 microgram) in tissue. Radiat Environ Biophys (1977) 1.13
Photodynamic effect of haematoporphyrin throughout the cell cycle of the human cell line NHIK 3025 cultivated in vitro. Br J Cancer (1979) 1.05
Destruction of erythroleukemia, myelocytic leukemia and Burkitt lymphoma cells by photoactivated protoporphyrin. Int J Cancer (1980) 1.04
Interstitial photoradiation therapy for primary solid tumors in pet cats and dogs. Cancer Res (1981) 1.02
The direct determination of porphyrin carboxylic acids. High-pressure liquid chromatography with solvent systems containing phase-transfer agents. Biochem J (1978) 1.00
Photodynamic killing of retinoblastoma cells with hematoporphyrin and light. Cancer Res (1979) 0.95
Multiplication of human NHIK 3025 cells exposed to porphyrins in combination with light. Br J Cancer (1981) 0.95
Photochemotherapy of glioma cells by visible light and hematoporphyrin. Cancer Res (1975) 0.95
Photodynamic inactivation of synchronized human cells in vitro in the presence of hematoporphyrin. Cancer Res (1979) 0.94
Haematoporphyrin diacetate: a probe to distinguish malignant from normal tissue by selective fluorescence. Br J Exp Pathol (1980) 0.91
Cytotoxic effect of hemin and protoporphyrin on chronic lymphocytic leukemia lymphocytes. Exp Hematol (1980) 0.84
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
Is azathioprine a better immunosuppressive than 6-mercaptopurine? Clin Exp Immunol (1971) 3.47
The structure of bilirubin. Proc R Soc Lond B Biol Sci (1978) 2.98
Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol (1977) 2.89
Postoperative depression of the lymphocyte response to phytohaemagglutinin. Lancet (1967) 2.57
Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49
The expected effect of a combination of agents: the general solution. J Theor Biol (1985) 2.06
The meso-reactivity of porphyrins and related compounds. VI. Oxidative cleavage of the haem system. The four isomeric biliverdins of the IX series. J Chem Soc Perkin 1 (1973) 1.92
The porphyrin pigmentation of subspecies of Bacteroides melaninogenicus. Biochem J (1979) 1.77
Photodynamic destruction of human bladder carcinoma. Br J Cancer (1975) 1.55
Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. Br J Cancer (1986) 1.53
Structure of bilirubin. Nature (1976) 1.48
Time-dependent immunosuppressive effects of anti-thymocyte serum. Nature (1967) 1.48
meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer (1986) 1.47
Dose-response curves for agents that impair cell reproductive integrity. A fundamental difference between dose-response curves of antimetabolites and those for radiation and alkylating agents. Br J Cancer (1969) 1.44
Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer (1991) 1.42
Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res (1974) 1.36
Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer (1993) 1.32
Depression of lymphocyte responses after surgical trauma. Br J Exp Pathol (1973) 1.29
Correlations between methods for measurement of synergy. J Infect Dis (1980) 1.29
Concerning the structure of photobilirubin II. Biochem J (1982) 1.27
The growth of human tumours in immunosuppressed mice and their response to chemotherapy. Br J Cancer (1974) 1.27
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. Cancer Chemother Rep (1972) 1.26
Cell respiration as a requirement for antibody release in vitro. Nature (1968) 1.21
Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J (1989) 1.19
Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Relation to immunosuppression induced by trauma. Clin Exp Immunol (1976) 1.11
The meso-reactivity of porphyrins and related compounds. V. The meso-oxidation of metalloporphyrins. J Chem Soc Perkin 1 (1972) 1.10
Reaction of acidified nitrite solutions with peptide derivatives: evidence for nitrosamine and thionitrite formation from 15N N.m.r. studies. J Chem Soc Perkin 1 (1975) 1.04
The therapeutic significance of the dose response curve for antilymphocytic serum. Transplantation (1971) 1.02
The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01
The direct determination of porphyrin carboxylic acids. High-pressure liquid chromatography with solvent systems containing phase-transfer agents. Biochem J (1978) 1.00
Immunosuppression by L-asparaginase. Nature (1970) 0.99
Photodynamic therapy with m-tetrahydroxyphenylchlorin in vivo: optimization of the therapeutic index. Int J Cancer (1993) 0.98
The relation between the physico-chemical properties and immunosuppressive effects of an homologous series of sulphonic acid esters. Immunology (1967) 0.97
Cobyric acid and related compounds from vitamin B12. J Chem Soc Perkin 1 (1969) 0.96
Effects of L-asparaginase on lymphocyte-target cell reactions in vitro. Nature (1970) 0.95
The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice. Br J Cancer (1971) 0.95
Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother (1983) 0.95
Mechanisms of the photodegradation of bilirubin. Biochem Soc Trans (1976) 0.94
Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. Br J Cancer (1985) 0.94
Immunosuppressive agents: the design of selective therapeutic schedules. Antibiot Chemother (1969) 0.93
The meso-reactivity of porphyrins and related compounds. 3. Deuteriation. J Chem Soc Perkin 1 (1967) 0.92
Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers Surg Med (1996) 0.92
The rabbit VX2 tumour as a model for carcinomas of the tongue and larynx. Acta Otolaryngol (1989) 0.91
Metabolism of biliverdin. Biliary excretion of bile pigments after intravenous injection of biliverdin isomers. Biochim Biophys Acta (1976) 0.90
Synergy assessment with growth curves. J Infect Dis (1984) 0.90
Radiosensitivity of immunologically activated cells. Nature (1966) 0.89
Minor synergy and antagonism may be clinically important. J Antimicrob Chemother (1987) 0.88
Determination of 5,10,15,20-tetra-(m-hydroxyphenyl)chlorin in tissues by high performance liquid chromatography. Biomed Chromatogr (1993) 0.87
Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine. Transplantation (1975) 0.87
HPD - a study of its components and their properties. Adv Exp Med Biol (1983) 0.87
The localization of haemolytic antibody in sections of lymphoid organs: an improved method. Immunology (1970) 0.84
Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage. J Antimicrob Chemother (1988) 0.84
Role of mitosis and mitotic inhibition in the immunosuppressive action of thioguanine. Nature (1966) 0.83
Consequences of synergy between environmental carcinogens. Environ Res (1985) 0.82
Protective effects of a novel perfluorochemical emulsion in photodynamic therapy. Biomater Artif Cells Immobilization Biotechnol (1992) 0.82
Nature of the tumor-localizing components of hematoporphyrin derivative. Cancer Res (1987) 0.82
Time-dependence and selectivity of immunosuppressive agents. Immunology (1979) 0.82
The effect of cysteine on the immunosuppressive activity of busulphan, cyclophosphamide and nitrogen mustard. Br J Cancer (1971) 0.82
The triplet and radical species of haematoporphyrin and some of its derivatives. Photochem Photobiol (1983) 0.81
Effect of cyclophosphamide on the homograft response in the guinea pig. Transplantation (1965) 0.81
Transplantation and immunosuppression. Mod Trends Immunol (1967) 0.81
Nitrosation and nitrosylation of haemoproteins and related compounds. Part 4. Pentaco-ordinate nitrosylprotohaem as the pigment of cooked cured meat. Direct evidence from E.S.R. spectroscopy. J Chem Soc Perkin 1 (1980) 0.81
Effect of some metabolic inhibitors on plaque formation in Jerne plates. Nature (1967) 0.81
Isoindole. J Chem Soc Perkin 1 (1973) 0.81
Photophysical properties of meso-tetraphenylporphyrin and some meso-tetra(hydroxyphenyl)porphyrins. Photochem Photobiol (1988) 0.80
Differential asparaginase sensitivity of T-cell and B-cell responses. Clin Exp Immunol (1973) 0.80
The formation of metal octamethyltetrabenzoporphyrins from isoindole precursors. J Chem Soc Perkin 1 (1972) 0.80
The mode of action of cytotoxic drugs. Proc R Soc Med (1970) 0.80
Porphyrin sensitizers in tumour phototherapy. Novel sensitizers of the chlorin and bacteriochlorin class with amphiphilic properties. J Photochem Photobiol B (1990) 0.79
Cyano-13-epicobalamin(neovitamin B 12 )and its relatives. J Chem Soc Perkin 1 (1971) 0.78
Letter: Predicting response of human cancer to chemotherapy. Lancet (1974) 0.78
Research ethics and deception. Lancet (1980) 0.78
Application of analytical and semi-preparative high-performance liquid chromatography to anthracyclines and bis-anthracycline derivatives. J Chromatogr (1984) 0.78
Immunosuppressive agents: generation and consequences of differing dose-response curves. Proc R Soc Med (1972) 0.78
Photobilirubin II. Biochem J (1984) 0.78
Perfluorochemicals and photodynamic therapy in mice. Adv Exp Med Biol (1990) 0.77
Intercellular immunological controls and modulation of cyclic AMP levels. Some doubts. Immunology (1976) 0.77
Photodynamic therapy of a mouse glioma: intracranial tumours are resistant while subcutaneous tumours are sensitive. Br J Cancer (1991) 0.77
Oxygen activation and tetrapyrroles. Essays Biochem (1981) 0.77
Neutrophil function during chemotherapy for Hodgkin's disease. Br J Cancer (1981) 0.77
Immunosuppression by platinum diamines. Br J Cancer (1971) 0.77
Interaction of nitrite with haems and related compounds. IARC Sci Publ (1976) 0.77
Mutagenicity of nitrosated alpha-amino acid derivatives N-acetyl-N'-nitrosotryptophan and its methyl ester in bacteria. Carcinogenesis (1980) 0.77
The meso-reactivity of porphyrins and related compounds. Part VII. Benzoyloxylation of phenylpyrroles and of octaethylporphyrin. J Chem Soc Perkin 1 (1976) 0.76
The effect on photohaemolysis of variation in the structure of the porphyrin photosensitizer. Biochem J (1985) 0.75
Singlet oxygen in the photo-oxidation of bilirubin in hydroxylic solvents. Biochem J (1972) 0.75
Autoimmunity and immunosuppression. Proc R Soc Med (1967) 0.75
Determination of 5,10,15,20-tetra-(m-hydroxyphenyl)chlorin in human plasma by high performance liquid chromatography. Biomed Chromatogr (1993) 0.75
Dose-response curves for agents that impair cell reproductive integrity. The relation between dose-response curves and the design of selective regimens in cancer chemotherapy. Br J Cancer (1969) 0.75
Concepts for describing the interaction of two agents. Radiat Res (1991) 0.75
Modes of action of immunosuppressive agents. Proc R Soc Med (1967) 0.75